Focus Partners Advisor Solutions LLC Purchases Shares of 14,946 Illumina, Inc. $ILMN

Focus Partners Advisor Solutions LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,946 shares of the life sciences company’s stock, valued at approximately $2,628,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new position in shares of Illumina during the fourth quarter valued at about $25,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina during the 4th quarter valued at about $26,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina during the 4th quarter valued at about $26,000. Activest Wealth Management increased its stake in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares during the period. Finally, Quarry LP bought a new stake in shares of Illumina in the 3rd quarter valued at approximately $32,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ ILMN opened at $190.89 on Friday. The business has a 50 day simple moving average of $183.78 and a 200 day simple moving average of $150.56. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a market cap of $28.82 billion, a price-to-earnings ratio of 35.61, a PEG ratio of 2.69 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ILMN shares. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Royal Bank Of Canada lifted their price objective on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Canaccord Genuity Group upped their target price on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Guggenheim lifted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $188.40.

Insider Activity at Illumina

In related news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 283,269 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the completion of the transaction, the director directly owned 2,089,425 shares of the company’s stock, valued at approximately $417,070,124.25. The trade was a 11.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,415,351 shares of company stock valued at $255,966,311. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.